This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial.
90 patients will be enrolled in this trial to examine the pathological Complete Response
defined as the absence of residual tumor in lung and lymph nodes comparing patients treated
with chemo-immunotherapy versus chemotherapy alone.